相关实验视频
Updated: Feb 17, 2026

09:31
Calcium Carbonate Formation in the Presence of Biopolymeric Additives
Published on: May 14, 2019
17.4K
一种基于功能化碳酸的高度吸收基质,用于通过滴滴剂量分配对克洛尼丁的个性化剂量
T Lashkari1, W E Hennink1, S M Hassanizadeh2
1Division of Pharmaceutics, Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht 3584 CG, the Netherlands.
International journal of pharmaceutics
|February 15, 2026
概括
研究人员开发了由功能化碳酸 (FCC) 制成的多孔片,用于个性化药物输送. 这些药片可以吸收药物墨水,以精确剂量,显示为定制儿科高血压治疗的潜力.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 药物输送系统 药物输送系统
背景情况:
- 精准医学需要可定制的药物输送解决方案.
- 现有的系统可能无法充分满足个性化剂量需求,特别是低剂量药物.
研究的目的:
- 开发和评估多孔片作为基板,用于点滴剂量个人化药物剂量.
- 为此应用评估使用功能化碳酸 (FCC) 的可行性.
主要方法:
- 来自功能化碳酸 (FCC) 的压缩多孔片,含有微晶纤维素 (MCC) 或乙烯纤维素 (EC) 结合剂.
- 优化的粘合剂比率和结合方法 (内微粒/外微粒).
- 装有克隆尼丁化墨水的片剂,并在酸性介质中进行溶解研究.
主要成果:
- 含有特定MCC或EC粘合剂度的药片成功吸收了30微升含有药物的墨水.
- 溶解研究表明,在模拟的胃条件下,在1-2小时内几乎完全释放药物.
- 当装有水性墨水时,FCC平板保持完整性.
结论:
- 功能化碳酸 (FCC) 孔隙片是适合滴滴剂系统的基板.
- 这种方法对个性化医疗有前途,特别是对于小儿高血压中低剂量药物,如克洛尼丁化.
- 开发的系统为可定制的药物输送提供了一个可行的平台.
相关概念视频
Oral Drug Delivery Systems: Continuous-Release Systems
21
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
21
Modified-Release Drug Delivery Systems: Rate-Programmed I
17
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
17
Ophthalmic Drug Delivery Systems
27
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
27
Modified-Release Drug Delivery Systems: Rate-Programmed II
6
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
6
Oral Drug Delivery Systems: Introduction
22
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
22
Drug Delivery Systems: Different Types
16
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
16

